Provasculon Company
.jpg)
Provasculon develops novel forms of stromal cell-derived factor-1 for the treatment of cardiovascular diseases and diabetic ulcers.
Total Funding:
$7 250 000
Employee Number:
1-10
Last Funding Date:
2011-11-09
Funding Status:
Early Stage Venture
Founded Date:
2007-01-01
Industry:
General Healthcare
Headquarters:
Cambridge, Massachusetts, United States
Last Funding Type:
Debt Financing